Systems biology, metabolic modelling and metabolomics in drug discovery and development

by: Douglas B Kell

Drug Discovery Today, Vol. 11, No. 23-24. (December 2006), pp. 1085-1092.

View FullText article

DOI, Pubmed, Hubmed, ScienceDirect

Reviews [Write a review of this article]

There are no reviews of this article

Find related articles from these CiteULike users

irenas, nicklynch, alexg, dullhunk, mhucka, raiyar, fishtank, steinmetzlab (group), shikin, GeneGo (group), alanrw, gemmalholliday

Find related articles with these CiteULike tags

biology, cassman-workshop, drugdiscovery, file-import-08-05-28, from-kell, genomics, metabolic, metabolic_profiling, metabolic-review, metabolism, metabolomics, methodspaper, model, network, new, prediction, review, sysbio, systems, systems_biology

Abstract

Unlike signalling pathways, metabolic networks are subject to strict stoichiometric constraints. Metabolomics amplifies changes in the proteome, and represents more closely the phenotype of an organism. Recent advances enable the production (and computer-readable encoding as SBML) of metabolic network models reconstructed from genome sequences, as well as experimental measurements of much of the metabolome. There is increasing convergence between the number of human metabolites estimated via genomics (~3000) and the number measured experimentally. It is thus both timely, and now possible, to bring these two approaches together as an integrated (if distributed) whole to help understand the genesis of metabolic biomarkers, the progress of disease, and the modes of action, efficacy, off-target effects and toxicity of pharmaceutical drugs.

@article{citeulike:971966, abstract = {Unlike signalling pathways, metabolic networks are subject to strict stoichiometric constraints. Metabolomics amplifies changes in the proteome, and represents more closely the phenotype of an organism. Recent advances enable the production (and computer-readable encoding as SBML) of metabolic network models reconstructed from genome sequences, as well as experimental measurements of much of the metabolome. There is increasing convergence between the number of human metabolites estimated via genomics (\~{}3000) and the number measured experimentally. It is thus both timely, and now possible, to bring these two approaches together as an integrated (if distributed) whole to help understand the genesis of metabolic biomarkers, the progress of disease, and the modes of action, efficacy, off-target effects and toxicity of pharmaceutical drugs.}, author = {Kell, Douglas B. }, citeulike-article-id = {971966}, doi = {http://dx.doi.org/10.1016/j.drudis.2006.10.004}, journal = {Drug Discovery Today}, keywords = {metabolism, systems\_biology}, month = {December}, number = {23-24}, pages = {1085--1092}, posted-at = {2007-08-06 06:27:02}, priority = {5}, title = {Systems biology, metabolic modelling and metabolomics in drug discovery and development}, url = {http://dx.doi.org/10.1016/j.drudis.2006.10.004}, volume = {11}, year = {2006} }

RIS record

TY - JOUR ID - citeulike:971966 L3 - citeulike-article-id:971966 TI - Systems biology, metabolic modelling and metabolomics in drug discovery and development JF - Drug Discovery Today VL - 11 IS - 23-24 SP - 1085 EP - 1092 N2 - Unlike signalling pathways, metabolic networks are subject to strict stoichiometric constraints. Metabolomics amplifies changes in the proteome, and represents more closely the phenotype of an organism. Recent advances enable the production (and computer-readable encoding as SBML) of metabolic network models reconstructed from genome sequences, as well as experimental measurements of much of the metabolome. There is increasing convergence between the number of human metabolites estimated via genomics (~3000) and the number measured experimentally. It is thus both timely, and now possible, to bring these two approaches together as an integrated (if distributed) whole to help understand the genesis of metabolic biomarkers, the progress of disease, and the modes of action, efficacy, off-target effects and toxicity of pharmaceutical drugs. KW - metabolism KW - systems_biology AU - Kell, Douglas PY - 2006/12// UR - http://dx.doi.org/10.1016/j.drudis.2006.10.004 ER -

RIS BibTeX